Fiche publication
Date publication
février 2025
Journal
Translational oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DEDIEU Stéphane
,
Dr DEVY Jérôme
,
Dr ETIQUE Nicolas
,
Pr MERROUCHE Yacine
,
Pr PAPATHANASSIOU Dimitri
,
Pr ROUX Stéphane
Tous les auteurs :
Jean C, Roux S, Aziz A, Mocquery-Corre M, Bazzi R, Merrouche Y, Dedieu S, Etique N, Papathanassiou D, Devy J
Lien Pubmed
Résumé
Radiolabeled molecules have become valuable tools in the diagnosis, monitoring, and treatment of cancer, particularly breast cancer. Through the use of radiotracers, clinicians can target specific tumor cells, assess microenvironments, and identify metastases. These radiopharmaceuticals, based on radionuclides, enable both imaging and therapeutic applications, leading to personalized cancer treatment. Techniques such as PET, SPECT, and the use of nanoparticles for theranostics are at the forefront of innovation, offering improved precision in both diagnosis and therapy. This review explores the various ways in which radiotracers are leveraged in modern oncology, with a focus on breast cancer, and highlights recent advancements in targeted radionuclide therapy and nanoparticle-based applications.
Mots clés
Breast cancer, Nanoparticles, Radiopharmaceuticals, Radiotracers, Targeted radionuclide therapy
Référence
Transl Oncol. 2025 02 6;53:102304
